Publicaciones (29) Publicaciones de Elena Perez Ceballos

2023

  1. Accuracy and prognostic impact of FDG PET/CT and biopsy in bone marrow assessment of follicular lymphoma at diagnosis: A Nation-Wide cohort study

    Cancer Medicine, Vol. 12, Núm. 6, pp. 6536-6546

2022

  1. IBRORS-MCL study: a Spanish retrospective and observational study of relapsed/refractory mantle-cell lymphoma treated with ibrutinib in routine clinical practice

    International Journal of Hematology, Vol. 116, Núm. 3, pp. 381-392

2017

  1. Bone marrow biopsy superiority over PET/CT in predicting progression-free survival in a homogeneously-treated cohort of diffuse large B-cell lymphoma

    Cancer Medicine, Vol. 6, Núm. 11, pp. 2507-2514

  2. Comorbidities, not age, are predictive of survival after autologous hematopoietic cell transplantation for relapsed/refractory Hodgkin’s lymphoma in patients older than 50 years

    Annals of Hematology, Vol. 96, Núm. 1, pp. 9-16

  3. Rituximab response in follicular lymphoma is associated with the rs20575 polymorphism in TRAILR1 extrinsic apoptosis trigger

    Pharmacogenetics and Genomics, Vol. 27, Núm. 2, pp. 70-77

2016

  1. A polymorphism in FASL is associated with rituximab response in follicular lymphoma patients

    American Journal of Hematology

  2. Blastic plasmacytoid dendritic cell neoplasm frequently shows occult central nervous system involvement at diagnosis and benefits from intrathecal therapy

    Oncotarget, Vol. 7, Núm. 9, pp. 10174-10181

  3. Phase II trial of ofatumumab plus ESHAP (O-ESHAP) as salvage treatment for patients with relapsed or refractory classical Hodgkin lymphoma after first-line chemotherapy

    British Journal of Haematology, Vol. 174, Núm. 6, pp. 859-867

  4. Recommendations on the clinical use of bendamustine in lymphoproliferative syndromes and multiple myeloma

    European Journal of Haematology, Vol. 96, Núm. 5, pp. 532-540

2015

  1. The role of bone marrow biopsy and FDG-PET/CT in identifying bone marrow infiltration in the initial diagnosis of high grade non-Hodgkin B-cell lymphoma and Hodgkin lymphoma. accuracy in a multicenter series of 372 patients

    American Journal of Hematology, Vol. 90, Núm. 8, pp. 686-690

2014

  1. Association of polymorphisms in TRAIL1 and TRAILR1 genes with susceptibility to lymphomas

    Annals of Hematology, Vol. 93, Núm. 2, pp. 243-247

  2. Intensification treatment based on early FDG-PET in patients with high-risk diffuse large B-cell lymphoma: A phase II GELTAMO trial

    British Journal of Haematology, Vol. 167, Núm. 3, pp. 327-336

2013

  1. Polymorphisms in xenobiotic metabolizing genes (EPHX1, NQO1 and PON1) in lymphoma susceptibility: A case control study

    BMC Cancer, Vol. 13

2012

  1. Role of GSTT1 and M1 null genotypes as risk factors for B-cell lymphoma: Influence of geographical factors and occupational exposure

    Molecular Carcinogenesis, Vol. 51, Núm. 6, pp. 508-513

2010

  1. Clinical significance of occult cerebrospinal fluid involvement assessed by flow cytometry in non-Hodgkin's lymphoma patients at high risk of central nervous system disease in the rituximab era

    European Journal of Haematology, Vol. 85, Núm. 4, pp. 321-328

  2. Reactivación de la hepatitis B en un paciente HBsAg negativo/antiHBc positivo con linfoma B que recibió quimioterapia con rituximab

    Gastroenterologia y Hepatologia, Vol. 33, Núm. 5, pp. 377-381

2008

  1. Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: High response rate and disease eradication

    Clinical Cancer Research, Vol. 14, Núm. 1, pp. 155-161

  2. Inhibition of proteasome by bortezomib causes intracellular aggregation of hepatic serpins and increases the latent circulating form of antithrombin

    Laboratory Investigation, Vol. 88, Núm. 3, pp. 306-317

2007

  1. Antithrombin Cambridge II (A384S): An underestimated genetic risk factor for venous thrombosis

    Blood, Vol. 109, Núm. 10, pp. 4258-4263

  2. Evaluation of four rapid methods for hemoglobin screening of whole blood donors in mobile collection settings

    Transfusion and Apheresis Science, Vol. 36, Núm. 3, pp. 235-242